An Icer white paper provides ammunition for both PBMs and pharma before the next Capitol Hill hearing.
The failure of one of Allergan’s key pipeline projects puts the group’s chief executive under even more pressure.
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
Biogen’s $877m buyout of Nightstar Therapeutics provides yet more evidence that gene therapy is reaching critical mass.
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.
Executives were pressed to lower prices in a post-rebate world, but a broad commitment to offset rebates did not materialise.
The Swiss group picks up Spark Therapeutics for $4.8bn, marking the biggest gene therapy buyout since Novartis’s $8.7bn move on Avexis.
Promising retinitis pigmentosa results have given Reneuron a boost, but the company still faces a pivotal trial.
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.